Diabetes mellitus with severe insulin resistance in a young male patient with a heterozygous pathogenic IRS1 frameshift variant.

IF 1 Q4 ENDOCRINOLOGY & METABOLISM
Clinical Pediatric Endocrinology Pub Date : 2024-01-01 Epub Date: 2024-02-23 DOI:10.1297/cpe.2023-0081
Yamato Osawa, Nobutaka Ichiwata, Junko Kenmotsu, Tsuyoshi Okada, Yohei Masunaga, Tsutomu Ogata, Ichiro Morioka, Tatsuhiko Urakami
{"title":"Diabetes mellitus with severe insulin resistance in a young male patient with a heterozygous pathogenic <i>IRS1</i> frameshift variant.","authors":"Yamato Osawa, Nobutaka Ichiwata, Junko Kenmotsu, Tsuyoshi Okada, Yohei Masunaga, Tsutomu Ogata, Ichiro Morioka, Tatsuhiko Urakami","doi":"10.1297/cpe.2023-0081","DOIUrl":null,"url":null,"abstract":"<p><p>We present the case of a young male patient (height, 158.1 cm [+3.3 standard deviation (SD)]; weight, 63.7 kg [body mass index, 25.5]) with diabetes mellitus and severe insulin resistance associated with a heterozygous pathogenic insulin receptor substrate 1 (<i>IRS1</i>) frameshift mutation. The patient also had severe acanthosis nigricans. Notably, the patient's father was undergoing treatment with high doses of insulin for diabetes mellitus, and had been experiencing angina pectoris. Laboratory data showed a fasting plasma glucose level of 88 mg/dL, hemoglobin A1C (HbA1c) of 7.4%, fasting insulin level of 43.1 µg/mL, and a homeostasis model assessment-insulin resistance (HOMA-IR) score of 9.36, indicating hyperinsulinism. Oral glucose tolerance test revealed a diabetic pattern and insulin hypersecretion. In addition, the patient had hyperlipidemia. Genetic studies revealed a heterozygous frameshift variant of <i>IRS1</i> [NM_005544.3:c.1791dupG:p.(His598Alafs*13)] in the patient and his father, which can impair the binding and activation of phosphoinositide 3 (PI-3) kinase and defectively mediate the translocation of glucose transporter type 4 (GLUT4) in adipose tissues, possibly leading to glucose intolerance. Therefore, this variant may be disease causing. After confirming <i>IRS1</i> mutation, metformin was administered, and physical exercise and dietary management were initiated; metformin was well tolerated, and optimal glycemic control was maintained.</p>","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985017/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pediatric Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1297/cpe.2023-0081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

We present the case of a young male patient (height, 158.1 cm [+3.3 standard deviation (SD)]; weight, 63.7 kg [body mass index, 25.5]) with diabetes mellitus and severe insulin resistance associated with a heterozygous pathogenic insulin receptor substrate 1 (IRS1) frameshift mutation. The patient also had severe acanthosis nigricans. Notably, the patient's father was undergoing treatment with high doses of insulin for diabetes mellitus, and had been experiencing angina pectoris. Laboratory data showed a fasting plasma glucose level of 88 mg/dL, hemoglobin A1C (HbA1c) of 7.4%, fasting insulin level of 43.1 µg/mL, and a homeostasis model assessment-insulin resistance (HOMA-IR) score of 9.36, indicating hyperinsulinism. Oral glucose tolerance test revealed a diabetic pattern and insulin hypersecretion. In addition, the patient had hyperlipidemia. Genetic studies revealed a heterozygous frameshift variant of IRS1 [NM_005544.3:c.1791dupG:p.(His598Alafs*13)] in the patient and his father, which can impair the binding and activation of phosphoinositide 3 (PI-3) kinase and defectively mediate the translocation of glucose transporter type 4 (GLUT4) in adipose tissues, possibly leading to glucose intolerance. Therefore, this variant may be disease causing. After confirming IRS1 mutation, metformin was administered, and physical exercise and dietary management were initiated; metformin was well tolerated, and optimal glycemic control was maintained.

一名患有杂合子致病性 IRS1 框移变异的年轻男性患者患上糖尿病并伴有严重的胰岛素抵抗。
我们报告了一例年轻男性患者的病例(身高 158.1 厘米 [+3.3 标准差 (SD)];体重 63.7 千克 [体重指数 25.5]),该患者患有糖尿病和严重的胰岛素抵抗,并伴有杂合子致病性胰岛素受体底物 1(IRS1)框移突变。患者还患有严重的黑棘皮症。值得注意的是,患者的父亲正在接受大剂量胰岛素治疗糖尿病,并一直有心绞痛症状。实验室数据显示,患者空腹血浆葡萄糖水平为 88 mg/dL,血红蛋白 A1C(HbA1c)为 7.4%,空腹胰岛素水平为 43.1 µg/mL,稳态模型评估-胰岛素抵抗(HOMA-IR)评分为 9.36,表明患者存在高胰岛素血症。口服葡萄糖耐量试验显示出糖尿病模式和胰岛素分泌过多。此外,患者还患有高脂血症。遗传学研究发现,患者及其父亲体内存在一个IRS1杂合子框架移位变异体[NM_005544.3:c.1791dupG:p. (His598Alafs*13)],该变异体可损害磷酸肌酸3(PI-3)激酶的结合和激活,并缺陷性地介导葡萄糖转运体4型(GLUT4)在脂肪组织中的转位,可能导致葡萄糖不耐受。因此,这种变异可能会导致疾病。在确认IRS1基因突变后,患者服用了二甲双胍,并开始进行体育锻炼和饮食管理;患者对二甲双胍的耐受性良好,血糖控制也保持在最佳水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Pediatric Endocrinology
Clinical Pediatric Endocrinology ENDOCRINOLOGY & METABOLISM-
CiteScore
2.40
自引率
7.10%
发文量
34
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信